STOCK TITAN

Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Axcella Therapeutics (Nasdaq: AXLA) announced its participation in the H.C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022. The company's management will engage in a fireside chat and hold one-on-one meetings, starting at 3:00 PM Eastern Time. Investors can access the webcast through the company’s website, with an archived replay available for 90 days. Axcella focuses on multi-targeted endogenous metabolic modulators to treat complex diseases, with significant developments in therapies for Long COVID and NASH.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 6th Annual NASH Investor Conference taking place virtually on October 17th, 2022.

Details for the fireside chat are as follows:

 

Date:

 

Monday, October 17th, 2022

 

Time:

 

3:00 pm Eastern Time

 

Webcast:

 

https://journey.ct.events/view/6b38c477-2942-428b-aed6-b4f7a0dcea88

The webcast will be accessible in the Investors & News section on the company’s website at www.axcellatx.com. An archive of the webcast replay will be available on the Company’s website for up to 90 days.

To request a one-on-on virtual meeting, please contact meetings@hcwco.com.

Internet Posting of Information

Axcella uses the “Investors and News” section of its website, www.axcellatx.com, as a means of disclosing material nonpublic information, to communicate with investors and the public, and for complying with its disclosure obligations under Regulation FD. Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts. The information that we post on our website could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

About Axcella Therapeutics (Nasdaq: AXLA)

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and NASH. The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.

LifeSci Advisors

Ashley Robinson

arr@lifesciadvisors.com

(617) 430-7577

Source: Axcella Therapeutics

FAQ

When is Axcella Therapeutics participating in the NASH Investor Conference?

Axcella Therapeutics is participating in the NASH Investor Conference on October 17, 2022, at 3:00 PM Eastern Time.

How can I access the Axcella Therapeutics webcast for the NASH Investor Conference?

The webcast for Axcella Therapeutics can be accessed on the company’s website, and will be available for replay for up to 90 days.

What is the focus of Axcella Therapeutics?

Axcella Therapeutics focuses on developing multi-targeted endogenous metabolic modulators to treat complex diseases, including therapies for Long COVID and NASH.

What is the stock symbol for Axcella Therapeutics?

The stock symbol for Axcella Therapeutics is AXLA.

Where can I find more information about Axcella Therapeutics and its products?

More information about Axcella Therapeutics and its products can be found on their website at www.axcellatx.com.

Axcella Health Inc.

NASDAQ:AXLA

AXLA Rankings

AXLA Latest News

AXLA Stock Data

1.18M
1.07M
15.8%
55.8%
2.65%
Biotechnology
Healthcare
Link
United States
Cambridge